Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. - Test2 - elhamkhani - TriplyDB

Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.

Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.

http://www.wikidata.org/entity/Q35157851

about

A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches Interferon (IFN)-γ-mediated inflammation and the kynurenine pathway in relation to bone mineral density: the Hordaland Health Study.Interplay between craniofacial stem cells and immune stimulus Updates on osteonecrosis of the jaw Compromised osseous healing of dental extraction sites in zoledronic acid-treated dogs.Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible.Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw Diabetes as a risk factor for medication-related osteonecrosis of the jaw.Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.Osteonecrosis of the Jaw Developed in Mice: DISEASE VARIANTS REGULATED BY γδ T CELLS IN ORAL MUCOSAL BARRIER IMMUNITY.Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass.Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth Immune modulation of CD4(+)CD25(+) regulatory T cells by zoledronic acid Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation.Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration.Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat.Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.Allogeneic mesenchymal stem cell therapy for bisphosphonate-related jaw osteonecrosis in Swine.IFN-γ and TNF-α synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFκB signaling.Pathophysiology of Osteonecrosis of the Jaws.Bisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β Mechanism.OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw.Effect of alendronate on bone remodeling around implant in the rat.Osteonecrosis of the jaw from bone anti-resorptives: impact of skeletal site-dependent mesenchymal stem cells.The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.In situ guided tissue regeneration in musculoskeletal diseases and aging : Implementing pathology into tailored tissue engineering strategies.Interactions between immune system and mesenchymal stem cells in dental pulp and periapical tissues.Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.Current status of drug therapies for osteoporosis and the search for stem cells adapted for bone regenerative medicine.Immunomodulation regulates mesenchymal stem cell-based bone regeneration.Effects of alendronate on the peri-implant bone in rats.Effect of alendronate on healing of extraction sockets and healing around implants.Hyperbaric oxygen therapy and osteonecrosis.Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis.Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.

P2860

Q27302911-39CED05F-DE17-4B8B-AF9C-1734C17512C6 Q28072449-716C6B4B-D8B2-4379-AE0B-3DE6BFED7764 Q33562127-8D5E058D-2E13-4245-A8C7-0074C156AB7E Q33830344-185E2E1B-9502-4E4F-B742-1C4985353CBD Q34234108-CDADD83B-45BE-4F8A-BBC5-6C81ED56CDEC Q34393622-0034D392-674A-406C-B5A9-B03B2721D280 Q34429959-800761E7-C304-4102-9EB3-6DCBC493ABF8 Q34635733-0CD75D68-4F9A-407E-8458-56FD58D0685D Q35219480-854A73C1-5B70-4F85-80F6-4B659A1C22B7 Q35627669-280620F5-CB19-470A-B117-6C7FE7CE6B70 Q35646110-AF717EC3-929A-4F62-80DB-65A6F642C895 Q35764778-60FB6750-2E28-4455-A64B-3DB9412A2572 Q35766784-89C4F6E3-2DA3-44EE-B12F-91220AAB7169 Q35837168-044DAE4F-BF04-4928-888D-C34185A841BB Q36040583-406FD102-D249-4C79-8F0C-8DB7BD73D12B Q36092153-B18C9A41-7F89-4554-B2B0-B80ACF5CD86E Q36204083-CCDE129D-1326-4AE8-AF1D-3390D8DF6083 Q36299558-D50F24D3-B3B5-4A49-8618-1689949E62A3 Q36375063-7EF00453-B254-4489-92CC-5CF9038EC49C Q36681335-BBF3C4DA-16F3-4C71-9D9E-11CBCACFD762 Q36945036-D2CD1070-5AFD-41EE-8616-0C24C2048921 Q36977598-866F360A-1654-4D99-A39C-65809A04EF51 Q36997344-07FF9EBF-AD51-41C5-B3D9-909FB89DFF75 Q37006852-B21BA73C-4BAF-4407-80CF-DE01977C9E0E Q37087037-6C141DD2-22DF-4442-B1BC-7EA9972013A0 Q37199204-6FA99358-428E-4DEB-BDE6-7AAEC3E42FE2 Q37363602-FA02C359-7B16-449F-A4AF-767EE123E9B0 Q37397269-E367C85B-58CB-4E10-B16E-D96FA72C0CF7 Q37623865-1044AC77-EEB9-4A4B-A50E-28ED8CCBB8DE Q37832692-277DC07C-EECA-4A64-8F27-1474993E8246 Q37947420-AA594EE9-6181-4FC3-B519-884198610C16 Q37994779-B7B0F426-9684-4C5B-B2C4-6FADFD7C4B90 Q38104993-968DA9DE-A03D-4389-BDA1-23FB89BB75CE Q38156028-5CE5C130-0A89-4DB7-9BEF-95E86A462A78 Q38203944-B6791E0E-7F30-427C-8A3F-8FB6A9FD1847 Q38438261-D1DCBE91-73CB-4327-9CC0-21B849DF816F Q38472238-6BAB5887-6E60-4B6F-AA47-24E402E15E48 Q38803408-9459C89E-BC8D-4C54-96D7-59C41C216174 Q38848433-F189AE12-DAD6-4017-8322-0A3CEEB05B2D Q38913031-51C36F7A-5F64-4A8B-B6C7-F050B9305F2D

P2860

Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.

http://www.wikidata.org/entity/Q35157851

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cell-based immunotherapy with ...... the jaw-like disease in mice.

@ast

Cell-based immunotherapy with ...... the jaw-like disease in mice.

@en

type

label

Cell-based immunotherapy with ...... the jaw-like disease in mice.

@ast

Cell-based immunotherapy with ...... the jaw-like disease in mice.

@en

prefLabel

Cell-based immunotherapy with ...... the jaw-like disease in mice.

@ast

Cell-based immunotherapy with ...... the jaw-like disease in mice.

@en

P1433

Q35157851-4D523D6F-5FDE-4F04-A581-30DE8EA28547

P1476

Q35157851-BB9091A0-98B5-402D-816D-4583DEFF90E3

P2093

Q35157851-15A5C4B4-6678-4BA5-B19C-87061DC74492

Q35157851-19B9BDF9-26CF-4388-830A-44A0A38B2506

Q35157851-238A0E57-78E6-442B-B1D7-D8C3C3ABBE89

Q35157851-387FB21C-E14E-426A-96DC-839E80092DD6

Q35157851-4784818B-AAB8-432A-9B1C-339949F1AA01

Q35157851-4F28019B-6361-48C3-85CC-18B7DED962B4

Q35157851-69EED147-741B-4B85-AFC9-7F82E4D6838F

Q35157851-7C1ABC7F-A58C-47DE-AD03-7AFFCF79995E

Q35157851-B8397B12-1365-436F-A0D8-DDC577F236E5

Q35157851-E69D3D2F-9E99-4FAD-A9FC-B2BA3F55CB7D

P2860

Q35157851-0992B216-9D5E-4B4D-BE65-2D68AD2E5990

Q35157851-0BD756FE-69E9-474E-9CF0-289428CF29A1

Q35157851-0BD94524-AD59-4149-8C50-D7ABA8739EB0

Q35157851-1102C40C-A25C-428B-A213-BEBB8CFF974C

Q35157851-1628C56C-0744-4AEF-8DFD-A63D78B22F3C

Q35157851-2DAECED6-9867-4AD9-A7E3-8AD8821725C9

Q35157851-334ADF2E-3CFB-486C-A4F3-FB7071314362

Q35157851-3BC66379-9A10-4BB8-9941-32C30BFFD44E

Q35157851-42201CD7-386A-4401-BB1F-B97B6BFC5AC5

Q35157851-45094001-F3CA-4EF1-B498-5BCF5408DD02

P304

Q35157851-3F20E01C-0ABD-4613-AAC3-D7AEFC15D783

P31

Q35157851-2BF49BE7-5FBF-49E6-8FAC-7DDC3B4362DB

P356

Q35157851-24FCFD2A-617F-4F4D-A52A-98B0DAD6FC8F

P433

Q35157851-2A519F99-0015-41A1-9084-031E91A1BC11

P478

Q35157851-78C600AE-951F-4E23-A692-3C565F2E1480

P577

Q35157851-44B88FEC-2B9E-4152-B85B-A8FDA9AC75D1

P5875

Q35157851-08B7A66D-E4E7-4E76-A56F-52EC660C2DC1

P698

Q35157851-84C2A65B-DB5C-41AF-AD16-E46C943D82DD

P921

Q35157851-C701B36F-F913-4B9B-B822-A4D42BD580B8

P932

Q35157851-756C47B7-F516-44A2-9536-79DB821AD5CE

P356

P1433

Journal of Bone and Mineral Research

P1476

Cell-based immunotherapy with ...... the jaw-like disease in mice.

@en

P2093

Anh D Le

http://www.w3.org/2001/XMLSchema#string

Chider Chen

http://www.w3.org/2001/XMLSchema#string

Insoo Kim

http://www.w3.org/2001/XMLSchema#string

Kentaro Akiyama

http://www.w3.org/2001/XMLSchema#string

Qunzhou Zhang

http://www.w3.org/2001/XMLSchema#string

Songlin Wang

http://www.w3.org/2001/XMLSchema#string

Songtao Shi

http://www.w3.org/2001/XMLSchema#string

Takashi Kikuiri

http://www.w3.org/2001/XMLSchema#string

Takyoshi Yamaza

http://www.w3.org/2001/XMLSchema#string

WanJun Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.

Bisphosphonates: mechanism of action and role in clinical practice

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

Regulatory T cells and immune tolerance

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

P304

1668-1679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.37

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41722760

http://www.w3.org/2001/XMLSchema#string

P698

20200952

http://www.w3.org/2001/XMLSchema#string

P921

P932

3154005

http://www.w3.org/2001/XMLSchema#string